Therapy Areas: Oncology
Gilead Names Shaw as Chief Executive Officer of Kite
15 July 2019 - - Christi L. Shaw will join US-based Gilead Sciences, Inc. (NASDAQ: GILD) as chief executive officer of Kite, a Gilead company, and will become a member of Gilead's senior leadership team, the company said.
Shaw has experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry.
She currently serves as senior vice president of Eli Lilly and Co., and president of Lilly Bio-Medicines.
Shaw also serves as a board member of both Avantor, Inc. and the biotechnology Industry Organization, and as an advisor to the Healthcare Businesswomen's Association.
Prior to joining Lilly, Shaw most recently served as US Country Head and president of Novartis Corp. and North American Head of Novartis Oncology.
She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin.
Kite, a Gilead company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies.
The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.